Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Mar 22:16:13.
doi: 10.1186/s12894-016-0133-y.

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

Shimpei Yamashita  1 , Yasuo Kohjimoto  2 , Takashi Iguchi  2 , Hiroyuki Koike  2 , Hiroki Kusumoto  2 , Akinori Iba  2 , Kazuro Kikkawa  2 , Yoshiki Kodama  2 , Nagahide Matsumura  2 , Isao Hara  2
Affiliations
Observational Study

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

Shimpei Yamashita et al. BMC Urol. .

Abstract

Background: While novel drugs have been developed, docetaxel remains one of the standard initial systemic therapies for castration-resistant prostate cancer (CRPC) patients. Despite the excellent anti-tumor effect of docetaxel, its severe adverse effects sometimes distress patients. Therefore, it would be very helpful to predict the efficacy of docetaxel before treatment. The aims of this study were to evaluate the potential value of patient characteristics in predicting overall survival (OS) and to develop a risk classification for CRPC patients treated with docetaxel-based chemotherapy.

Methods: This study included 79 patients with CRPC treated with docetaxel. The variables, including patient characteristics at diagnosis and at the start of chemotherapy, were retrospectively collected. Prognostic factors predicting OS were analyzed using the Cox proportional hazard model. Risk stratification for overall survival was determined based on the results of multivariate analysis.

Results: PSA response ≥50 % was observed in 55 (69.6 %) of all patients, and the median OS was 22.5 months. The multivariate analysis showed that age, serum PSA level at the start of chemotherapy, and Hb were independent prognostic factors for OS. In addition, ECOG performance status (PS) and the CRP-to-albumin ratio were not significant but were considered possible predictors for OS. Risk stratification according to the number of these risk factors could effectively stratify CRPC patients treated with docetaxel in terms of OS.

Conclusions: Age, serum PSA level at the start of chemotherapy, and Hb were identified as independent prognostic factors of OS. ECOG PS and the CRP-to-albumin ratio were not significant, but were considered possible predictors for OS in Japanese CRPC patients treated with docetaxel. Risk stratification based on these factors could be helpful for estimating overall survival.

Keywords: Castration-resistant prostate cancer; Docetaxel; Prognostic factor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Waterfall plot of PSA response. PSA responses of ≥0 %, ≥30 %, and ≥50 % are seen in 69 (87.3 %), 64 (81.0 %), and 55 (69.6 %) patients, respectively
Fig. 2
Fig. 2
Kaplan-Meier curves for overall survival (OS) according to risk group classification
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocrine-Related Cancer. 2010;17(4):R305–R315. doi: 10.1677/ERC-10-0187. - DOI - PMC - PubMed
    1. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate. 2004;61(4):332–353. doi: 10.1002/pros.20115. - DOI - PubMed
    1. Shiota M, Yokomizo A, Naito S. Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. Endocrine-related Cancer. 2012;19(6):R243–R253. doi: 10.1530/ERC-12-0232. - DOI - PubMed
    1. Sadar MD. Small molecule inhibitors targeting the “achilles’ heel” of androgen receptor activity. Cancer Res. 2011;71(4):1208–1213. doi: 10.1158/0008-5472.CAN_10-3398. - DOI - PMC - PubMed
    1. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England J Med. 2012;367(13):1187–1197. doi: 10.1056/NEJMoa1207506. - DOI - PubMed

Publication types

MeSH terms